Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation

NCT04890613 is registered in ClinicalTrials.gov with Senhwa Biosciences, Inc. as lead sponsor.

NCT NCT04890613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04890613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Expansion Study of CX-5461 in Patients With Solid Tumours and BRCA2 and/or PALB2 Mutation
Lead sponsor
Senhwa Biosciences, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
September 8, 2021
Completion date
March 31, 2027
Enrollment
52 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor